Myung‐Ju Ahn
机构：Samsung Medical Center, Hanyang University Medical Center, Hanyang University, Sungkyunkwan University · ORCID：0000-0002-5740-9654
发表论文 1304 篇 · 总被引 74520 次 · h-index 110
代表论文
- Osimertinib Plus Gefitinib in Patients with EGFR -Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD (2026 · Clinical Cancer Research · 被引 1)
- Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer (2026 · Future Oncology · 被引 1)
- Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody (2026)
- Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody (2026)
- Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody (2026)
- Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody (2026)